Position in GILD
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$171,843,210
New position
Shares Held
1,233,000
first reported quarter
Ownership
0.099%
of shares outstanding
% of Portfolio
0.75%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 99.81605839416059.ToString("F0")%
Shared 0.ToString("F0")%
None 0.18394160583941604.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026SEB Asset Management AB holds $2,746,586,901 across 11 Drug Manufacturers - General names. GILD ranks #7 (6.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
5,954,417 | $1,174,330,120 | |
| 2 | LLY |
ELI LILLY & Co
|
387,272 | $356,201,167 | |
| 3 | JNJ |
Johnson & Johnson
|
1,286,484 | $314,468,148 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
3,586,365 | $217,513,037 | |
| 5 | ABBV |
AbbVie Inc.
|
946,326 | $205,816,441 | |
| 6 | MRK |
Merck & Co., Inc.
|
1,642,285 | $197,550,462 | |
| 7 | GILD |
Gilead Sciences, Inc.
This page
|
1,233,000 | $171,843,210 | |
| 8 | AMGN |
Amgen Inc
|
180,676 | $63,570,850 |
All Filings in GILD
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $171,843,210 | 1,233,000 | Shares | Sole | 2026-05-07 | |
| No filing history on record for this holder in this stock. | ||||||